Screener
Haemonetics HAE EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Haemonetics’s reported figures.
Based on trailing twelve months.
The source filing: Haemonetics’s 10-Q, filed February 5, 2026. Open the filing →
- Filed
- Feb 5, 2026, 6:05 AM EST
- Fiscal quarter
- Q3 FY2026
- Calendar quarter
- Q4 2025
- Accession
- 0000313143-26-000010
FAQ
- What is Haemonetics's EBITDA margin?
- Haemonetics (HAE) reported EBITDA margin of 27.6% in Q4 2025.
- How has Haemonetics's EBITDA margin changed year-over-year?
- Haemonetics's EBITDA margin increased by 28.3% year-over-year, from 21.5% to 27.6%.
- What is the long-term trend for Haemonetics's EBITDA margin?
- Over 4 years (2021 to 2025), Haemonetics's EBITDA margin has grown at a 5.5% compound annual growth rate (CAGR), from 20% to 24.8%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.
Ask your AI about Haemonetics's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude